SBI Securities’s Black Diamond Therapeutics BDTX Stock Holding History

SBI Securities’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$194	Hold	103	–	–	﹤0.01%	3427
2026 Q2	$191	Hold	103	–	–	﹤0.01%	3341
2026 Q1	$219	Hold	103	–	–	﹤0.01%	3186
2025 Q4	$250	Sell	103 -4	-4%	-$14	﹤0.01%	3141
2025 Q3	$406	Sell	107 -49	-31%	-$143	﹤0.01%	3054
2025 Q2	$387	Sell	156 -192	-55%	-$370	﹤0.01%	3068
2025 Q1	$539	Buy	348 +195	+127%	+$409	﹤0.01%	2842
2024 Q4	$327	Buy	+153	New	+$438	﹤0.01%	3051

Other funds holding BDTX

DLK Investment Management Solana Beach, California $275M AUM 10.69% 1-Year Est. Return

Kathmere Capital Management Wayne, Pennsylvania $2.07B AUM 20.3% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

SBI Securities's BDTX Position: Q3 2026 in Review

SBI Securities held its Black Diamond Therapeutics (BDTX) position steady in Q3 2026 at 103 shares worth $194. The position accounts for ﹤0.01% of the portfolio, ranked #3427.

SBI Securities first reported a position in BDTX in Q4 2024 and has held it in 8 quarters since. The position peaked at $539 in Q1 2025. 10 funds tracked by Wall St. Rank hold BDTX as of Q3 2026.

SBI Securities held 103 shares of Black Diamond Therapeutics worth $194 as of Q3 2026.
SBI Securities left its Black Diamond Therapeutics share count unchanged in Q3 2026.
Black Diamond Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #3427 holding.
SBI Securities first reported a position in Black Diamond Therapeutics in Q4 2024 and has held it in 8 quarters since.
SBI Securities's Black Diamond Therapeutics position peaked at $539 in Q1 2025.
10 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.